Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - doxorubicini hydrochloridum - soluzione iniettabile - doxorubicini hydrochloridum 20 mg, natrii chloridum corresp. natrium 35.4 mg, acidum hydrochloridum, aqua ad iniectabile, ad solutionem pro 10 ml. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - doxorubicini hydrochloridum - soluzione iniettabile - doxorubicini hydrochloridum 50 mg, natrii chloridum corresp. natrium 88.5 mg, acidum hydrochloridum, aqua ad iniectabile, ad solutionem pro 25 ml. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - doxorubicini hydrochloridum - soluzione iniettabile - doxorubicini hydrochloridum 100 mg, natrii chloridum corresp. natrium 177 mg, acidum hydrochloridum, aqua ad iniectabile, ad solutionem pro 50 ml. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - doxorubicini hydrochloridum - soluzione iniettabile - doxorubicini hydrochloridum 200 mg, natrii chloridum corresp. natrium 354 mg, acidum hydrochloridum, aqua ad iniectabile, ad solutionem pro 100 ml. - farmaco - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doxorubicina cloridrato - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - agenti antineoplastici - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).